CLINICAL OUTCOMES OF AXITINIB VERSUS SUNITINIB AS A FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN JAPANESE PATIENTS

被引：0
|
作者：
Kiso, Yusuke
Inoue, Takamitsu
Nara, Taketoshi
Kanda, Sohei
Numakura, Kazuyuki
Tsuruta, Hiroshi
Saito, Mitsuru
Narita, Shintaro
Satoh, Shigeru
Habuchi, Tomonori
机构：
来源：
JOURNAL OF UROLOGY | 2018年 / 199卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP66-16
引用
收藏
页码：E874 / E874
页数：1
相关论文
共 50 条
  • [1] Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era
    Numakura, Kazuyuki
    Muto, Yumin
    Naito, Sei
    Hatakeyama, Shingo
    Kato, Renpei
    Koguchi, Tomoyuki
    Kojima, Takahiro
    Kawasaki, Yoshihide
    Kandori, Syuya
    Kawamura, Sadafumi
    Arai, Yoichi
    Ito, Akihiro
    Nishiyama, Hiroyuki
    Kojima, Yoshiyuki
    Obara, Wataru
    Ohyama, Chikara
    Tsuchiya, Norihiko
    Habuchi, Tomonori
    [J]. CANCER MEDICINE, 2021, 10 (17): : 5839 - 5846
  • [2] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] Axitinib as first-line therapy in metastatic renal cell carcinoma
    Nozawa, Masahiro
    Uemura, Hirotsugu
    [J]. TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 555 - 557
  • [4] Axitinib versus sunitinib as first-line therapies for metastatic renal cell carcinoma: A multicenter retrospective analysis.
    Hatakeyama, Shingo
    Tanaka, Toshiaki
    Ikehata, Yoshinori
    Fujita, Naoki
    Masumori, Naoya
    Kitamura, Hiroshi
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Ohyama, Chikara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.
    Bracarda, Sergio
    Bamias, Aristotelis
    Casper, Jochen
    Negrier, Sylvie
    Sella, Avishay
    Staehler, Michael D.
    Tarazi, Jamal Christo
    Felici, Alessandra
    Rosbrook, Brad
    Jardinaud-Lopez, Monica
    Escudier, Bernard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [6] Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma
    Chen, Chi-Chang
    Hess, Gregory P.
    Liu, Zhimei
    Gesme, Dean H.
    Agarwala, Sanjiv S.
    Garay, Carlos C.
    Hill, Jerrold W.
    Guo, Amy
    [J]. CLINICAL GENITOURINARY CANCER, 2012, 10 (04) : 256 - 261
  • [7] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    [J]. ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
  • [8] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez
    Luis León
    Ovidio Fernández
    Martín Lázaro
    Enrique Grande
    Luis Aparicio
    [J]. Advances in Therapy, 2012, 29 : 202 - 217
  • [9] COMPARATIVE EFFICACY OF SUNITINIB VERSUS SORAFENIB AS THE FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Park, S. J.
    Lee, J.
    Park, I.
    Park, K.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 287 - 288
  • [10] The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma
    Kameda, Tomohiro
    Takayama, Tatsuya
    Sugihara, Toru
    Takeshima, Saki
    Yamazaki, Masahiro
    Komatsubara, Maiko
    Kamei, Jun
    Fujisaki, Akira
    Ando, Satoshi
    Kurokawa, Shinsuke
    Fujimura, Tetsuya
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (04) : 241 - 246
12345